SG Americas Securities LLC Raises Stock Position in PTC Therapeutics, Inc. $PTCT

SG Americas Securities LLC lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 2,679.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 130,097 shares of the biopharmaceutical company’s stock after purchasing an additional 125,417 shares during the quarter. SG Americas Securities LLC’s holdings in PTC Therapeutics were worth $7,984,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in PTCT. AlphaQuest LLC increased its stake in PTC Therapeutics by 337.7% during the 2nd quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock worth $386,000 after buying an additional 6,102 shares during the period. Vise Technologies Inc. purchased a new position in PTC Therapeutics in the 2nd quarter valued at approximately $486,000. Prudential Financial Inc. grew its stake in shares of PTC Therapeutics by 35.5% in the second quarter. Prudential Financial Inc. now owns 84,250 shares of the biopharmaceutical company’s stock worth $4,115,000 after acquiring an additional 22,060 shares in the last quarter. Hussman Strategic Advisors Inc. increased its position in shares of PTC Therapeutics by 200.0% during the second quarter. Hussman Strategic Advisors Inc. now owns 63,000 shares of the biopharmaceutical company’s stock worth $3,077,000 after acquiring an additional 42,000 shares during the period. Finally, Y Intercept Hong Kong Ltd increased its position in shares of PTC Therapeutics by 458.8% during the second quarter. Y Intercept Hong Kong Ltd now owns 27,832 shares of the biopharmaceutical company’s stock worth $1,359,000 after acquiring an additional 22,851 shares during the period.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent quarterly results showed an upside surprise (EPS and revenue beat), supporting valuation and reducing near-term execution risk. MarketBeat PTCT Summary
• Positive Sentiment: At least one independent researcher upgraded PTC from Hold to Buy (Wall Street Zen), and several firms have raised price targets in November — a bullish offset to otherwise muted analyst sentiment. Wall Street Zen Upgrade
• Neutral Sentiment: Analysts as a group still carry a consensus “Hold” rating on PTCT, indicating limited immediate upside from broker consensus alone. Analyst Consensus
• Neutral Sentiment: The company reported a routine inducement grant of 300 RSUs for a new non-executive hire under Nasdaq rules — small dilution and not material to fundamentals. PR Newswire
• Negative Sentiment: A director executed a large sale totaling $916,200, a notable insider disposition that can weigh on sentiment. Director Sale
• Negative Sentiment: Broad insider selling reported in multiple SEC Form 4 filings (CEO, CFO, EVP, VP, CAO and others sold shares in early January). The scale and breadth of executive sales likely represent profit-taking or diversification and can create short-term downward pressure until offset by fresh operational news. Representative SEC filing: SEC Form 4
• Negative Sentiment: EVP Lee Scott Golden and other insiders sold modest-to-large blocks (multiple transactions disclosed), reinforcing the headline of concentrated insider exits. InsiderTrades Alert

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, insider Neil Gregory Almstead sold 71,928 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $83.44, for a total value of $6,001,672.32. Following the completion of the sale, the insider owned 100,625 shares in the company, valued at approximately $8,396,150. The trade was a 41.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Allan Steven Jacobson sold 14,199 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $83.55, for a total value of $1,186,326.45. Following the completion of the sale, the director directly owned 17,451 shares of the company’s stock, valued at $1,458,031.05. The trade was a 44.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 287,633 shares of company stock valued at $22,674,765 over the last 90 days. 5.50% of the stock is owned by insiders.

PTC Therapeutics Price Performance

NASDAQ PTCT opened at $77.53 on Friday. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The company has a market capitalization of $6.22 billion, a PE ratio of 9.06 and a beta of 0.49. The company has a fifty day moving average of $76.61 and a two-hundred day moving average of $62.72.

PTC Therapeutics (NASDAQ:PTCT) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business had revenue of $211.01 million for the quarter, compared to analysts’ expectations of $177.42 million. During the same quarter in the previous year, the firm earned ($1.39) earnings per share. The business’s revenue was up 7.2% compared to the same quarter last year. On average, research analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PTCT shares. Royal Bank Of Canada lowered PTC Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their target price for the company from $82.00 to $91.00 in a report on Monday, December 1st. TD Cowen lifted their price objective on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a research note on Wednesday, November 5th. Barclays boosted their price objective on PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $90.00 price target on shares of PTC Therapeutics in a research note on Thursday. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, PTC Therapeutics presently has an average rating of “Hold” and a consensus target price of $77.27.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.